Findings

What does this study add?

• Lebrikizumab delivered clinical efficacy, with a dose-dependent and significant improvement in the primary endpoint across all doses, with LS mean percentage change in EASI of –62.3, –69.2, –72.1 for the three lebrikizumab doses, compared to –41.1 for placebo.
• Disease severity as assessed by POEM (Patient Oriented Eczema Measure) was also improved at Week 16.
• Pruritus, sleep and quality of life were improved quickly – as early as Day 2 for pruritus, and Week 1 for sleep – and continued to improve to Week 16.
• Lebrikizumab was generally well tolerated, with a safety profile consistent with previous studies.